Hannah Clarke

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

We preview several noteworthy P2 presentations in the urologic oncology space.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

Overall, 71% of patients had no fragment greater than 2 mm following treatment.

There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD.

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.

Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.

Ian Metzler, MD, discusses developments in imaging and treating stones.

Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

“Given the rates in epidemiologic studies and surveys showing that up to 70% of women are symptomatic, we were surprised to find that only 9% [filled] a prescription,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

Sima P. Porten, MD, MPH, discusses the need to better understand how genetic makeup influences how individuals process environmental toxins.

“I think it will help patients decide what prostate surgery they want,” says Naeem Bhojani, MD, FRCSC.

“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.

An approach to WVTT involving 1 treatment per prostate lobe was associated with decreased post-operative complications.

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, MPH, FACS, URPS.

This approval marks the first clearance of a stapler designed for single-port robotic surgery in the US.

"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.

"We should not be preemptively reducing the dose for all our patients, because half of the patients will never develop grade 3/4 anemia," says Neeraj Agarwal, MD, FASCO.

In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.

“I think it's primarily due to dietary changes that are more and more prevalent regardless of sex,” says Ian Metzler, MD, MTM.

At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.

"“The approval of Gozellix is likely to both streamline and expand access to PSMA-PET imaging, hopefully broadening the distribution and use of gallium 68," says Kelly L. Stratton, MD, FACS.